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In the title molecule, C17H14O4, the C atom of the carboxyl
group deviates by 1.221 (3) A ˚ from the plane [maximum
deviation = 0.0122(2) A ˚ ] of the tricycic ring system. In the
crystal structure, intermolecular O—H   O hydrogen bonds
link the molecules into centrosymmetric dimers, and  – 
interactions [centroid–centroid distances = 3.491 (3),
3.591 (3), 3.639 (3) and 3.735 (3) A ˚ ] link these dimers into
layers parallel to the ac plane. Weak intermolecular C—H   O
interactions further consolidate the crystal packing.
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Table 1
Hydrogen-bond geometry (A ˚ ,  ).
D—H   AD —H H   AD    AD —H   A
O4—H4O   O3
iii 1.00 (2) 1.63 (2) 2.633 (1) 173.25 (2)
C16—H16B   O4
iv 0.99 2.52 3.460 (1) 158 (1)
Symmetry codes: (iii)  x þ 1; y þ 1; z þ 2; (iv)  x; y þ 1; z þ 2.
Data collection: CrystalClear (Rigaku/MSC, 2008); cell reﬁnement:
CrystalClear; data reduction: CrystalClear; program(s) used to solve
structure: SHELXS97 (Sheldrick, 2008); program(s) used to reﬁne
structure: SHELXL97 (Sheldrick, 2008); molecular graphics:
SHELXL97 (Sheldrick, 2008); software used to prepare material for
publication: publCIF (Westrip, 2010) and PLATON (Spek, 2009).
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Vadimezan: 2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid
S.-J. Zhang and W.-X. Hu
Comment
Tumor vascular disrupting agents (VDA) cause the established vascular structure inside a solid tumor to collapse, depriving
the tumor of blood, oxygen and nutrients it needs to survive (McKeage et al., 2010; Head et al., 2010; Ching, 2008; Patterson
et al., 2007; Hinnen et al., 2007; Lippert, 2007). A number of new drug-based VDAs have been developed that are believed
to be highly efficient, low toxic, and several of them are currently undergoing clinical trials, among which Vadimezan is the
most advanced in Phase III clinical development (Pili et al., 2010; McKeage et al., 2009; McKeage et al., 2008). The study
of antitumor mechanisms and signal pathways of Vadimezan is carried out (Zhan et al., 2010; Cheng et al., 2010; Roberts
et al., 2008), as well as the structure modification of xanthones (Gobbi et al., 2006; Woon et al., 2005).
The molecular structure of Vadimezan is very important and necessary in understanding of the compound and may help
to further elucidate its antivascular effect for the treatment of human cancer. Its crystal structure is reported for the first time
in this paper. The structure (Figure 1) is similar to other xanthones reported with an essential planar three-ring skeleton and
the C atom of the carboxyl group deviates at 1.221 (3) Å from the tricycle plane. In the crystal structure, intermolecular
O—H···O (Table 2) hydrogen bonds link the molecules into centrosymmetric dimers, and π-π interactions (Table 1) link
these dimers into layers parallel to ac plane. Weak intermolecular C—H···O interactions (Table 2) consolidate further the
crystal packing (Fig. 2).
Experimental
Vadimezan was prepared from 3,4-dimethylanthranilic acid according to literature method (Atwell et al., 2002). Diazotiz-
ation of 3,4-dimethylanthranilic acid with NaNO2 and then treatment with KI led to 3,4-dimethyl-2-iodobenzoic acid,
which was coupled with 2-hydroxyphenylacetic acid catalyzed by TDA-1 and Cu(I) in dried DMSO to obtain 2-[2-
(carboxylmethyl)phenoxy]-3,4-dimethylbenzoic acid. Finally, ring closure in sulfuric acid led to 5,6-dimethyl-9-oxoxan-
thene-4-acetic acid: white solid; mp: 529–532 K; PHPLC 98.2%; IR νmax (KBr)/cm-1: 2970, 1708, 1650, 1602, 1411, 1330,
1212, 768; 1H NMR (DMSO-d6, 500 MHz) δ: 12.60 (s, 1H, COOH), 8.07 (dd, J1 = 1.5 Hz, J2 = 8.0 Hz, 1H, Ar), 7.89 (d,
J = 8.0 Hz, 1H, Ar), 7.78 (dd, J1 = 1.3 Hz, J2 = 7.3 Hz, 1H, Ar), 7.40 (t, J = 7.5 Hz, 1H, Ar), 7.24 (d, J = 8.5 Hz, 1H, Ar),
3.95 (s, 2H, Ar—CH2), 2.39 (s, 3H, Ar—CH3), 2.36 (s, 3H, Ar—CH3); EIMS m/z(%): 282(M+, 77), 238 (42), 237 (100),
236 (26), 223 (17), 209 (37), 195 (12), 165 (28).
Refinement
H atom attached to carboxyl O atom was located in a difference map and refined with bond restraint O—H = 1.00 (2) Å.
C-bound H atoms were positioned geometrically (C—H 0.95 - 0.99 Å). All H atoms were refined as riding, with Uiso(H)
= 1.2 - 1.5 Ueq of the parent atoms. Hydrogen atoms attached to C14 are disordered with a refined site occupancy factor
0.50 for each H14A, H14B, H14C, H14D, H14E and H14F.supplementary materials
sup-2
Figures
Fig. 1. The molecular structure of (I) shown with 30% probability displacement ellipsoids.
One component of rotationally disordered methyl group (C14) is shown.




C17H14O4 Z = 2
Mr = 282.28 F(000) = 296
Triclinic, P1 Dx = 1.425 Mg m−3
a = 6.7854 (19) Å Mo Kα radiation, λ = 0.71073 Å
b = 9.826 (3) Å Cell parameters from 1944 reflections
c = 10.532 (3) Å θ = 3.0–27.5°
α = 71.435 (7)° µ = 0.10 mm−1
β = 82.741 (9)° T = 163 K
γ = 83.142 (9)° Block, colorless
V = 658.0 (3) Å3 0.50 × 0.50 × 0.37 mm
Data collection
Rigaku AFC10/Saturn724+
diffractometer 2304 reflections with I > 2σ(I)
Radiation source: Rotating Anode Rint = 0.018
graphite θmax = 27.5°, θmin = 3.4°
Detector resolution: 28.5714 pixels mm-1 h = −8→8
phi and ω scans k = −11→12
6284 measured reflections l = −13→13
2955 independent reflections
Refinement
Refinement on F2 Primary atom site location: structure-invariant direct
methodssupplementary materials
sup-3
Least-squares matrix: full Secondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.040
Hydrogen site location: inferred from neighbouring
sites
wR(F2) = 0.094




2) + (0.0346P)2 + 0.226P]
where P = (Fo
2 + 2Fc
2)/3
2955 reflections (Δ/σ)max < 0.001
195 parameters Δρmax = 0.26 e Å−3
0 restraints Δρmin = −0.17 e Å−3
Special details
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance mat-
rix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations
between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of
cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, convention-
al R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-
factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large
as those based on F, and R- factors based on ALL data will be even larger.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)
x y z Uiso*/Ueq Occ. (<1)
O1 0.21097 (13) 0.40487 (9) 0.72385 (9) 0.0215 (2)
O2 0.36821 (16) 0.20951 (10) 0.43040 (10) 0.0335 (3)
O3 0.49314 (15) 0.35197 (11) 0.95899 (10) 0.0312 (2)
O4 0.23835 (16) 0.47712 (12) 1.03729 (11) 0.0361 (3)
C1 0.3402 (2) 0.03641 (14) 0.70661 (15) 0.0278 (3)
H1 0.3796 −0.0144 0.6431 0.033*
C2 0.3195 (2) −0.03755 (15) 0.84129 (16) 0.0330 (3)
H2 0.3434 −0.1395 0.8710 0.040*
C3 0.2632 (2) 0.03676 (15) 0.93484 (15) 0.0306 (3)
H3 0.2494 −0.0159 1.0279 0.037*
C4 0.2271 (2) 0.18497 (14) 0.89551 (14) 0.0252 (3)
C5 0.18653 (18) 0.63568 (13) 0.56645 (13) 0.0208 (3)
C6 0.20182 (18) 0.72389 (13) 0.43318 (13) 0.0221 (3)
C7 0.25597 (19) 0.66243 (14) 0.32918 (13) 0.0248 (3)
H7 0.2664 0.7233 0.2386 0.030*
C8 0.29413 (19) 0.51639 (14) 0.35551 (13) 0.0238 (3)
H8 0.3301 0.4772 0.2833 0.029*
C9 0.32191 (19) 0.26831 (14) 0.51829 (13) 0.0232 (3)
C10 0.30347 (19) 0.18691 (14) 0.66213 (13) 0.0223 (3)
C11 0.24803 (18) 0.25830 (13) 0.75729 (13) 0.0212 (3)
C12 0.22678 (17) 0.48664 (13) 0.59068 (12) 0.0188 (3)
C13 0.28044 (18) 0.42500 (13) 0.48780 (13) 0.0202 (3)supplementary materials
sup-4
C14 0.1303 (2) 0.69521 (15) 0.68242 (14) 0.0298 (3)
H14A 0.1279 0.6159 0.7671 0.036* 0.50
H14B −0.0020 0.7477 0.6734 0.036* 0.50
H14C 0.2284 0.7608 0.6823 0.036* 0.50
H14D 0.1084 0.8004 0.6481 0.036* 0.50
H14E 0.2382 0.6686 0.7418 0.036* 0.50
H14F 0.0078 0.6554 0.7330 0.036* 0.50
C15 0.1628 (2) 0.88493 (14) 0.39994 (15) 0.0291 (3)
H15A 0.0275 0.9087 0.4362 0.035*
H15B 0.1761 0.9292 0.3021 0.035*
H15C 0.2594 0.9217 0.4399 0.035*
C16 0.1661 (2) 0.26804 (15) 0.99384 (14) 0.0293 (3)
H16A 0.1462 0.1991 1.0854 0.035*
H16B 0.0369 0.3240 0.9720 0.035*
C17 0.3156 (2) 0.36947 (15) 0.99384 (13) 0.0260 (3)
H4O 0.345 (3) 0.541 (2) 1.032 (2) 0.076 (7)*
Atomic displacement parameters (Å2)
U11 U22 U33 U12 U13 U23
O1 0.0261 (5) 0.0176 (4) 0.0205 (5) −0.0008 (3) −0.0016 (4) −0.0061 (4)
O2 0.0449 (6) 0.0277 (5) 0.0326 (6) 0.0000 (4) −0.0035 (5) −0.0171 (4)
O3 0.0298 (5) 0.0314 (5) 0.0339 (6) 0.0002 (4) −0.0023 (4) −0.0133 (4)
O4 0.0322 (6) 0.0397 (6) 0.0430 (6) 0.0003 (5) −0.0014 (5) −0.0241 (5)
C1 0.0279 (7) 0.0212 (7) 0.0377 (8) −0.0008 (5) −0.0081 (6) −0.0125 (6)
C2 0.0367 (8) 0.0185 (7) 0.0426 (9) −0.0008 (6) −0.0115 (7) −0.0053 (6)
C3 0.0334 (8) 0.0252 (7) 0.0295 (7) −0.0046 (6) −0.0071 (6) −0.0010 (6)
C4 0.0227 (7) 0.0253 (7) 0.0272 (7) −0.0041 (5) −0.0031 (5) −0.0063 (6)
C5 0.0184 (6) 0.0207 (6) 0.0249 (7) −0.0018 (5) −0.0017 (5) −0.0094 (5)
C6 0.0185 (6) 0.0198 (6) 0.0279 (7) −0.0021 (5) −0.0036 (5) −0.0063 (5)
C7 0.0239 (7) 0.0266 (7) 0.0215 (7) −0.0030 (5) −0.0030 (5) −0.0034 (5)
C8 0.0233 (7) 0.0278 (7) 0.0226 (7) −0.0029 (5) −0.0016 (5) −0.0108 (5)
C9 0.0211 (6) 0.0232 (7) 0.0290 (7) −0.0019 (5) −0.0038 (5) −0.0127 (6)
C10 0.0197 (6) 0.0206 (6) 0.0287 (7) −0.0021 (5) −0.0052 (5) −0.0089 (5)
C11 0.0185 (6) 0.0179 (6) 0.0273 (7) −0.0024 (5) −0.0042 (5) −0.0060 (5)
C12 0.0159 (6) 0.0199 (6) 0.0206 (6) −0.0030 (5) −0.0019 (5) −0.0058 (5)
C13 0.0175 (6) 0.0209 (6) 0.0241 (7) −0.0025 (5) −0.0030 (5) −0.0089 (5)
C14 0.0385 (8) 0.0228 (7) 0.0289 (7) −0.0018 (6) 0.0008 (6) −0.0108 (6)
C15 0.0318 (8) 0.0218 (7) 0.0317 (8) −0.0016 (5) −0.0032 (6) −0.0053 (6)
C16 0.0307 (7) 0.0295 (7) 0.0246 (7) −0.0036 (6) 0.0015 (6) −0.0053 (6)
C17 0.0320 (7) 0.0270 (7) 0.0165 (6) 0.0022 (6) −0.0036 (5) −0.0045 (5)
Geometric parameters (Å, °)
O1—C11 1.3690 (15) C7—C8 1.3708 (19)
O1—C12 1.3746 (15) C7—H7 0.9500
O2—C9 1.2301 (15) C8—C13 1.3953 (18)
O3—C17 1.2225 (17) C8—H8 0.9500
O4—C17 1.3108 (16) C9—C10 1.4680 (19)supplementary materials
sup-5
O4—H4O 1.00 (2) C9—C13 1.4688 (18)
C1—C2 1.370 (2) C10—C11 1.3883 (18)
C1—C10 1.4032 (18) C12—C13 1.3925 (17)
C1—H1 0.9500 C14—H14A 0.9800
C2—C3 1.395 (2) C14—H14B 0.9800
C2—H2 0.9500 C14—H14C 0.9800
C3—C4 1.3816 (19) C14—H14D 0.9800
C3—H3 0.9500 C14—H14E 0.9800
C4—C11 1.4011 (19) C14—H14F 0.9800
C4—C16 1.5030 (19) C15—H15A 0.9800
C5—C6 1.3937 (18) C15—H15B 0.9800
C5—C12 1.4031 (17) C15—H15C 0.9800
C5—C14 1.5045 (18) C16—C17 1.505 (2)
C6—C7 1.4021 (19) C16—H16A 0.9900
C6—C15 1.5057 (18) C16—H16B 0.9900
Cg1···Cg2i 3.491 (3) Cg2···Cg2i 3.735 (3)
Cg1···Cg2ii 3.591 (3) Cg2···Cg2ii 3.639 (3)
C11—O1—C12 119.45 (10) C12—C13—C9 120.73 (12)
C17—O4—H4O 109.3 (12) C8—C13—C9 121.21 (11)
C2—C1—C10 120.21 (13) C5—C14—H14A 109.5
C2—C1—H1 119.9 C5—C14—H14B 109.5
C10—C1—H1 119.9 H14A—C14—H14B 109.5
C1—C2—C3 120.06 (13) C5—C14—H14C 109.5
C1—C2—H2 120.0 H14A—C14—H14C 109.5
C3—C2—H2 120.0 H14B—C14—H14C 109.5
C4—C3—C2 121.64 (13) C5—C14—H14D 109.5
C4—C3—H3 119.2 H14A—C14—H14D 141.1
C2—C3—H3 119.2 H14B—C14—H14D 56.3
C3—C4—C11 117.33 (12) H14C—C14—H14D 56.3
C3—C4—C16 122.88 (13) C5—C14—H14E 109.5
C11—C4—C16 119.79 (12) H14A—C14—H14E 56.3
C6—C5—C12 117.71 (11) H14B—C14—H14E 141.1
C6—C5—C14 122.29 (11) H14C—C14—H14E 56.3
C12—C5—C14 120.00 (12) H14D—C14—H14E 109.5
C5—C6—C7 119.79 (12) C5—C14—H14F 109.5
C5—C6—C15 120.53 (11) H14A—C14—H14F 56.3
C7—C6—C15 119.67 (12) H14B—C14—H14F 56.3
C8—C7—C6 121.37 (12) H14C—C14—H14F 141.1
C8—C7—H7 119.3 H14D—C14—H14F 109.5
C6—C7—H7 119.3 H14E—C14—H14F 109.5
C7—C8—C13 120.32 (12) C6—C15—H15A 109.5
C7—C8—H8 119.8 C6—C15—H15B 109.5
C13—C8—H8 119.8 H15A—C15—H15B 109.5
O2—C9—C10 122.46 (12) C6—C15—H15C 109.5
O2—C9—C13 122.77 (12) H15A—C15—H15C 109.5
C10—C9—C13 114.77 (11) H15B—C15—H15C 109.5
C11—C10—C1 118.59 (12) C4—C16—C17 113.59 (11)
C11—C10—C9 120.20 (11) C4—C16—H16A 108.8supplementary materials
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C1—C10—C9 121.21 (12) C17—C16—H16A 108.8
O1—C11—C10 122.88 (12) C4—C16—H16B 108.8
O1—C11—C4 114.95 (11) C17—C16—H16B 108.8
C10—C11—C4 122.17 (12) H16A—C16—H16B 107.7
O1—C12—C13 121.97 (11) O3—C17—O4 123.02 (14)
O1—C12—C5 115.28 (11) O3—C17—C16 123.28 (12)
C13—C12—C5 122.75 (12) O4—C17—C16 113.68 (12)
C12—C13—C8 118.06 (11)
C10—C1—C2—C3 −0.5 (2) C16—C4—C11—O1 0.55 (18)
C1—C2—C3—C4 0.0 (2) C3—C4—C11—C10 −0.25 (19)
C2—C3—C4—C11 0.4 (2) C16—C4—C11—C10 −179.84 (12)
C2—C3—C4—C16 179.95 (13) C11—O1—C12—C13 −0.27 (17)
C12—C5—C6—C7 −0.03 (18) C11—O1—C12—C5 −179.83 (11)
C14—C5—C6—C7 179.62 (12) C6—C5—C12—O1 179.53 (11)
C12—C5—C6—C15 −179.37 (12) C14—C5—C12—O1 −0.13 (17)
C14—C5—C6—C15 0.28 (19) C6—C5—C12—C13 −0.03 (19)
C5—C6—C7—C8 0.2 (2) C14—C5—C12—C13 −179.69 (12)
C15—C6—C7—C8 179.51 (12) O1—C12—C13—C8 −179.58 (11)
C6—C7—C8—C13 −0.2 (2) C5—C12—C13—C8 −0.05 (19)
C2—C1—C10—C11 0.6 (2) O1—C12—C13—C9 0.23 (18)
C2—C1—C10—C9 −179.11 (13) C5—C12—C13—C9 179.75 (11)
O2—C9—C10—C11 −179.09 (12) C7—C8—C13—C12 0.19 (19)
C13—C9—C10—C11 0.80 (17) C7—C8—C13—C9 −179.61 (12)
O2—C9—C10—C1 0.6 (2) O2—C9—C13—C12 179.41 (12)
C13—C9—C10—C1 −179.46 (12) C10—C9—C13—C12 −0.47 (17)
C12—O1—C11—C10 0.62 (17) O2—C9—C13—C8 −0.8 (2)
C12—O1—C11—C4 −179.77 (11) C10—C9—C13—C8 179.32 (11)
C1—C10—C11—O1 179.34 (12) C3—C4—C16—C17 116.51 (15)
C9—C10—C11—O1 −0.91 (19) C11—C4—C16—C17 −63.93 (17)
C1—C10—C11—C4 −0.24 (19) C4—C16—C17—O3 −25.38 (19)
C9—C10—C11—C4 179.51 (12) C4—C16—C17—O4 155.89 (12)
C3—C4—C11—O1 −179.87 (11)
Symmetry codes: (i) −x+1, −y+1, −z+1; (ii) −x+2, −y+1, −z+1.
Hydrogen-bond geometry (Å, °)
D—H···A D—H H···A D···A D—H···A
O4—H4O···O3iii 1.00 (2) 1.63 (2) 2.633 (1) 173.25 (2)
C16—H16B···O4iv 0.99 2.52 3.460 (1) 158 (1)
Symmetry codes: (iii) −x+1, −y+1, −z+2; (iv) −x, −y+1, −z+2.supplementary materials
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